Description: Term products exhibit a wide range of behavior as policyholders can elect different term periods and conversion options. While term products have been around for decades, it's only recently that longer level term products are reaching the end of the level term period. Term conversions have historically been an afterthought and are rarely modeled. Discuss the use of predictive modeling techniques such as LASSO regression and cross-validation to build models for level term lapses and post-level term shock lapses, as well as the extrapolation of experience for shorter term products to longer term products (e.g., extrapolating 20-year term experience and applying to 30-year term). Explore the use of traditional techniques to develop term conversion rates and a framework for modeling the assumption. Challenges and limitations of setting lapse and conversion rates will be discussed. By attending the session, you will: - Understand the complexities of term policyholder behavior. - Understand the challenges in developing and implementing assumptions for lapses and conversions. - Understand the application of traditional and predictive modeling techniques for term policyholder behavior.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Dive into an overview of potential customer value propositions, trends in consumer acceptance and adoption, solving the data portability issue, potential impacts of emerging partner ships with OEMs and more within the auto insurance industry during our latest webcast. Experience interactive dialogue that will allow another dimension of thinking as industry experts provide insights and expertise. Throughout this webcast, you can expect developments in the personal lines automotive telematics-based insurance landscape that will develop a further understanding of the present and future of this industry.

Description: Explore insights to non-traditional actuarial roles from a panelist with experiences in data science, finance and entertainment. The panelist will be sharing their perspectives on their non-traditional actuarial role in relation to the actuarial profession.

Description: Explore insights to non-traditional actuarial roles from a panelist with experiences in data science, finance and entertainment. The panelist will be sharing their perspectives on their non-traditional actuarial role in relation to the actuarial profession.

Description: The Individual Life Experience Committee has numerous research projects underway. Take a look at three current areas of research: the analysis of the interaction of lapse and mortality experience using data from mandatory submissions; a deep dive into old age mortality; and an update on the committee's work to establish a predictive analytics framework that will be open for all actuaries and data scientists to use. By attending the session, you will: - Better understand the research conducted by the Individual Life Experience Committee. - Better understand the link between lapse and mortality experience, appreciate some of the nuances of older age mortality, and gain knowledge about a predictive analytics framework that will be released in the future.

Description: Are Accelerated Underwriting (AU) programs performing as expected? As mortality experience will (hopefully) be slow to emerge, it is pivotal that we look at alternative methods of monitoring early performance. From random hold outs, to post-issue APS's, and post-issue prescription profiles, explore popular monitoring techniques and lessons learned so far. Focus on confusion matrices that provide an early indication of mortality slippage relative to fluid-based underwriting decisions. Finally, explore statistical methods to determine what constitutes credibility and identify opportunities to think about mortality slippage more robustly.